Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

AlloCure Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapse

Coordinator
Universitaetsklinikum Freiburg, Germany
Runs
1 October 2023 to 30 September 2028
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101094168

What the project is doing

In the project's own words, from its summary on CORDIS.

Acute graft-versus-host disease (GVHD) and leukemia relapse cause 75% of the mortality of patients having undergone allogeneic hematopoietic cell transplantation (allo-HCT). A better understanding of signalling in immune cells, tissue specific cell types and leukemia cells is key to develop novel therapies against GVHD and leukemia relapse. The ambitious overall goal of AlloCure is to identify the pathogenic events that initiate GVHD (1), maintain therapy-refractory GVHD (2) and mediate immune escape causing leukemia relapse (3).

To address these high risk/high gain questions novel methods and developments across disciplines are required. (1) I hypothesize that a loss of to date unexplored intestinal enteroendocrine cells promotes GVHD initiation. To study these small cell subsets, we will use reporter genes and novel imaging methods to systematically evaluate their fate and signalling during intestinal GVHD. (2) Signalling propagating refractory GVHD is not well-understood.

Our phospho-proteomics data set from corticosteroid- and ruxolitinib-refractory GVHD patients will instruct selective analysis of kinase activation in immune cells and enterocytes by using genetic Cre-lox-based and pharmacological approaches. (3) I have shown that leukemia-derived lactic acid inhibits glycolysis and MEK/ERK signalling in T cells, thereby impairing graft-versus-leukemia (GVL) effects. Here, I will decipher which other leukemia-derived metabolites mediate pathogenic signalling in immune cells and test if oncogenic signalling in leukemia cells drives immunosuppressive metabolite production.

To enhance GVL we will inhibit pathogenic kinase activation in leukemia cells and myeloid suppressor cells. Using high risk/high gain approaches in a combination of murine and human studies AlloCure aims to develop individualized therapeutic strategies to interfere with pathogenic signalling responsible for GVHD or leukemia relapse to reduce the mortality rate of patients undergoing allo-HCT.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum FreiburgFreiburgGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI